IGXTinactive

INTELGENX TECHNOLOGIES CORP.

Healthcare·Neurology·Commercial
NeurologyPainReproductive

INTELGENX TECHNOLOGIES CORP. (IGXT): 7 pipeline candidates · ~1 mo cash runway. Updated within the last hour.

7.6/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.3

1.2 months

Financial Health10.0

D/E -1.43 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

7 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for INTELGENX TECHNOLOGIES CORP.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$772K

Quarterly Burn

$2.9M

Runway

1.2 mo

Revenue

$174K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2026
Today~7 mo out
Catalyst within runway

Pipeline (7 candidates)

·CEO: Dwight Gorham Dwight

Frequently asked questions

How many drug candidates are in INTELGENX TECHNOLOGIES CORP.'s pipeline?

INTELGENX TECHNOLOGIES CORP. (IGXT) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is INTELGENX TECHNOLOGIES CORP.'s lead drug candidate?

INTELGENX TECHNOLOGIES CORP.'s most advanced tracked candidate is cannabis infused versafilm (Approved) for adult-used medical cannabis.

What is INTELGENX TECHNOLOGIES CORP.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, INTELGENX TECHNOLOGIES CORP. has approximately 1.2 months of cash runway.

Who is the CEO of INTELGENX TECHNOLOGIES CORP.?

Dwight Gorham Dwight is the chief executive officer of INTELGENX TECHNOLOGIES CORP. (IGXT).

Get the full picture on INTELGENX TECHNOLOGIES CORP.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.